NanoString Technologies CEO and leadership

Brad Gray joined NanoString from Genzyme Genetics, the diagnostic services division of Genzyme Corporation, where he was most recently Vice President of Product & Business Development leading the development of molecular diagnostics and partnering activities. Mr. Gray held several strategy and business development roles at the corporate and division levels beginning in 2004 when he joined Genzyme Corporation as Director of Corporate Development. Previously, Mr. Gray was a management consultant in the healthcare practice of McKinsey & Company. He holds a B.A. in Economics and Management from Oxford University, where he studied as a British Marshall Scholar, and an S.B. in Chemical Engineering from the Massachusetts Institute of Technology.

K. Thomas Bailey has served as Chief Financial Officer since January 2018. Prior to joining our company, Mr. Bailey was Chief Financial Officer at AgaMatrix Holdings LLC, a developer, manufacturer and marketer of medical technologies for diabetes care, from March 2014 to January 2018. Prior to joining AgaMatrix, Mr. Bailey served as Chief Executive Officer of Angiotech Pharmaceuticals, a developer, manufacturer and marketer of local drug, drug delivery and medical device technologies, from October 2011 to October 2013, and served as Angiotech’s Chief Financial Officer from December 2005 to October 2011. During his time as CFO of Angiotech, Mr. Bailey directed a restructuring of Angiotech’s debt obligations pursuant to the Canadian Creditors Arrangement Act in 2011, with recognition of the restructuring pursuant to Chapter 15 under U.S. law. Mr. Bailey also serves as a Director of AgaMatrix Holdings, SCP Interventional Radiology LLC and The Homestretch Foundation, and previously served as a Director of Angiotech Pharmaceuticals, LifeCare Management Services and OncoGenex Inc. Previously, Mr. Bailey served as a Director in the health care investment banking group at Credit Suisse First Boston and Donaldson, Lufkin & Jenrette. Mr. Bailey received an A.B. in economics from Harvard University in 1990 and an M.B.A. from Harvard Business School in 1995.

Brad Gray joined NanoString from Genzyme Genetics, the diagnostic services division of Genzyme Corporation, where he was most recently Vice President of Product & Business Development leading the development of molecular diagnostics and partnering activities. Mr. Gray held several strategy and business development roles at the corporate and division levels beginning in 2004 when he joined Genzyme Corporation as Director of Corporate Development. Previously, Mr. Gray was a management consultant in the healthcare practice of McKinsey & Company. He holds a B.A. in Economics and Management from Oxford University, where he studied as a British Marshall Scholar, and an S.B. in Chemical Engineering from the Massachusetts Institute of Technology.